The optimal duration of antiplatelet therapy in high-bleeding risk (HBR) patients with coronary artery disease treated with newer-generation drug-eluting bioresorbable polymer-coated stents remains unclear.
Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study / Frigoli, Enrico; Smits, Pieter; Vranckx, Pascal; Ozaki, Yokio; Tijssen, Jan; Jüni, Peter; Morice, Marie-Claude; Onuma, Yoshinobu; Windecker, Stephan; Frenk, Andrè; Spaulding, Christian; Chevalier, Bernard; Barbato, Emanuele; Tonino, Pim; Hildick-Smith, David; Roffi, Marco; Kornowski, Ran; Schultz, Carl; Lesiak, Maciej; Iñiguez, Andrés; Colombo, Antonio; Alasnag, Mirvat; Mullasari, Ajit; James, Stefan; Stankovic, Goran; Ong, Paul J L; Rodriguez, Alfredo E; Mahfoud, Felix; Bartunek, Jozef; Moschovitis, Aris; Laanmets, Peep; Leonardi, Sergio; Heg, Dik; Sunnåker, Mikael; Valgimigli, Marco. - In: AMERICAN HEART JOURNAL. - ISSN 0002-8703. - 209:(2019), pp. 97-105. [10.1016/j.ahj.2018.10.009]
Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study
Barbato, EmanueleMembro del Collaboration Group
;
2019
Abstract
The optimal duration of antiplatelet therapy in high-bleeding risk (HBR) patients with coronary artery disease treated with newer-generation drug-eluting bioresorbable polymer-coated stents remains unclear.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
